ReviewFrontiers in immunology2026

Inter-assay variability in anti-JC virus serology in the era of natalizumab biosimilars: implications for PML risk stratification.

Ana Belén Caminero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.